Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…
AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.
Jeremy Clarkson treated for aggressive prostate cancer, now in remission / 16 days
Early‑onset cancers rising; family history crucial for prevention / 20 days
Ultrasensitive HPV blood test detects head and neck recurrence months earlier / 29 days
Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 6 wks
UK records highest-ever skin cancer cases; severe cases rise / 7 wks
Conflicting mammogram advice leaves patients and clinicians uncertain / 7 wks
AI face photos may predict cancer survival years earlier / 2 months
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.